Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer

Key Points

• The aim is to evaluate the efficacy of selpercatinib in patients with early-stage RET fusion-positive non-small-cell lung cancer.
• Randomized trial design with early-stage RET fusion-positive non-small-cell lung cancer patients.
• Intervention included selpercatinib treatment with follow-up assessments.
• Analyses of therapeutic outcomes and safety profiles conducted.
• Significant improvement in disease-free survival with selpercatinib, HR 0.45, 95% CI 0.30-0.68, p=0.0001.
• Enhanced overall response rate noted at 85% in the treatment group.
• Lower incidence of adverse events compared to standard therapies.